ABSTRACT
This systematic review to support the 2023 US Preventive Services Task Force Recommendation Statement on serologic screening for genital herpes summarizes published evidence on the benefits and harms of screening and interventions for genital herpes in asymptomatic sexually active adolescents, adults, and pregnant persons with no clinical history of genital herpes.
Subject(s)
Herpes Genitalis , Mass Screening , Serologic Tests , Humans , Advisory Committees , Herpes Genitalis/blood , Herpes Genitalis/diagnosis , Herpes Genitalis/prevention & control , United StatesABSTRACT
OBJECTIVES: Traditionally, subjects' migration status has usually been defined on the basis of their registered residency status. We attempted to redefine migration based on the duration of residency in their cities of migration and to explore more precisely the impact of migration on HIV infection risk in men who have sex with men (MSM). METHODS: A multisite cross-sectional study was conducted during 2012-2013 in seven Chinese cities. Questionnaire surveys were conducted and blood was drawn to test for antibodies to HIV, syphilis and herpes simplex virus-2 (HSV-2). MSM who were unregistered local residents and had resided in their cities of migration for ≤1 or >1â year were defined as migrant MSM, or transitional MSM, respectively. RESULTS: Compared with transitional MSM and local MSM, migrant MSM had poorer HIV knowledge and higher rates of high-risk behaviour, including earlier sexual debut, multiple sexual partners, participation in commercial sex and recreational drug use. Multivariate logistic regression analysis showed that HIV prevalence among migrant MSM was higher than local MSM (p<0.05). This relationship, however, did not hold for transitional MSM and local MSM (p>0.05). Male sex work, recreational drug use, syphilis infection and HSV-2 infection were independently associated with HIV infection among migrant MSM. CONCLUSIONS: Non-local MSM with shorter residence were at greater risk of HIV acquisition. More focus should be placed on HIV behavioural interventions targeting non-local MSM with temporary residence.
Subject(s)
HIV Infections/epidemiology , Health Knowledge, Attitudes, Practice , Sexual Behavior/statistics & numerical data , Transients and Migrants/statistics & numerical data , Adult , China/epidemiology , Cities/epidemiology , Cross-Sectional Studies , HIV Infections/blood , HIV Infections/diagnosis , Herpes Genitalis/blood , Herpes Genitalis/diagnosis , Herpes Genitalis/epidemiology , Homosexuality, Male , Humans , Male , Prevalence , Risk Factors , Risk-Taking , Sex Work/statistics & numerical data , Sexual Behavior/physiology , Sexual Partners , Sexual and Gender Minorities/psychology , Sexual and Gender Minorities/statistics & numerical data , Surveys and Questionnaires , Syphilis/blood , Syphilis/diagnosis , Syphilis/epidemiology , Transients and Migrants/psychology , Young AdultABSTRACT
Schizophrenia is a destructive clinical syndrome with diverse mental pathologies. Different mechanisms and factors have a role in this disease. A possible mechanism is that teratogenic viruses cause brain changes and results in the disease appearance. The schizophrenia patients were diagnosed by psychologists and with the consent of patients, five CC of venous blood was drawn. Than Serum samples were isolated and immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2) and cytomegalovirus (CMV) were quantified by ELISA sandwich kit. The Results showed that anti-CMV and anti-HSV1 and anti-HSV2 IgG antibodies in schizophrenia patients were increased significantly (p< 0.05). The increasing of the anti-HSV2 IgM was also observed but increasing amount of the anti-HSV1 IgM was not statistically significant (p< 0.05). Therefore, as a result of this study CMV and HSV1 and HSV2 infection can probably intensify the symptoms in schizophrenia patients.
Subject(s)
Antibodies, Viral/blood , Cytomegalovirus Infections/complications , Herpes Genitalis/complications , Herpes Simplex/complications , Immunoglobulin G/blood , Immunoglobulin M/blood , Schizophrenia/complications , Adult , Aged , Case-Control Studies , Cytomegalovirus/immunology , Cytomegalovirus/pathogenicity , Cytomegalovirus Infections/blood , Cytomegalovirus Infections/immunology , Cytomegalovirus Infections/virology , Enzyme-Linked Immunosorbent Assay , Female , Herpes Genitalis/blood , Herpes Genitalis/immunology , Herpes Genitalis/virology , Herpes Simplex/blood , Herpes Simplex/immunology , Herpes Simplex/virology , Herpesvirus 1, Human/immunology , Herpesvirus 1, Human/pathogenicity , Herpesvirus 2, Human/immunology , Herpesvirus 2, Human/pathogenicity , Humans , Male , Middle Aged , Schizophrenia/blood , Schizophrenia/immunology , Schizophrenia/virologyABSTRACT
We measured the microbial community structure of genital ulcers in women. Swabs from clinically detected ulcers were tested for HSV-2 and Treponema pallidum by polymerase chain reaction (PCR). HSV-2 and T. pallidum were detected by serum antibody testing. Microbial community structure was characterized by high-throughput 16 s rRNA gene amplicon sequencing. Multiple group testing and Elastic net and Lasso regressions identified taxa associated with differences in factors of interest. Among 49 ulcer specimens from 49 HSV-2 seropositive women, by PCR HSV-2 was recovered from 28 (57%) specimens and T. pallidum from none; one woman showed serologic evidence of syphilis. Overall, 63% of women were HIV-positive and 49% had an uncircumcised male sex partner. By both multiple group testing and regression, Porphyromonas (FDR p-value = 0.02), Prevotella (FDR p-value = 0.03), Anaerococcus (FDR p-value = 0.07), and Dialister (FDR p-value = 0.09) were detected at higher relative abundance in HSV-2 PCR-positive than negative ulcers. The presence of HSV-2 in a lesion was associated with presumed bacterial agents of Bacterial vaginosis. Differences in bacterial communities may contribute to HSV-2 ulcer pathogenesis, severity, or prolonged healing. If these results are confirmed, future studies may consider the influence of BV treatment on women's GUD and HSV-2 incidence and recurrence.
Subject(s)
Bacteria/isolation & purification , Herpes Genitalis/microbiology , Herpesvirus 2, Human/isolation & purification , Ulcer/microbiology , Vaginosis, Bacterial/microbiology , Adult , Bacteria/genetics , Female , Genitalia/microbiology , Genitalia/pathology , Herpes Genitalis/blood , Herpes Genitalis/pathology , Herpesvirus 2, Human/genetics , Humans , Kenya , Microbiota/genetics , Middle Aged , Pilot Projects , Polymerase Chain Reaction , Ulcer/blood , Ulcer/pathology , Vaginosis, Bacterial/blood , Vaginosis, Bacterial/pathology , Young AdultABSTRACT
OBJECTIVE: Depressed mood is common in pregnancy, is associated with stress, and could result in immune suppression that may lead to latent herpes viral reactivation. This study investigated whether depressed mood is associated with higher herpes viral IgG levels in pregnant women. METHODS: Complete cross-sectional data from 247 pregnant women were available for this substudy. The data included demographics, scores on the Perceived Stress Scale and Profile of Mood States (POMS), and a panel of serum IgG levels for human herpesviruses. RESULTS: Only the herpes simplex virus type 2 (HSV-2) (genital herpes) IgG level was associated with Perceived Stress Scale and POMS-Depression/Dejection (POMS-D) score. Hierarchical multiple regression analysis was used to examine the association of POMS-D with herpesviral IgG levels adjusting for demographic variables. In the final model, African American race (ß = .251, p < .001), older age (ß = .199, p = .002), single marital status (ß = -.304, p < .001), and depressed mood (ß = .122, p = .04) were associated with HSV-2 IgG levels. In logistic regression, the strongest correlates of HSV IgG positivity were single marital status, followed by POMS-D scores and African American race. CONCLUSION: Genital herpes is a concern in pregnancy. Antibody titers may indicate asymptomatic viral shedding, viral reactivation, or primary viral infection. Antibody levels may be higher because of the immune changes during pregnancy and potential immune effects of depressed mood causing reactivation of latent HSV-2.
Subject(s)
Antibodies, Viral/blood , Black or African American , Depressive Disorder/physiopathology , Herpesvirus 2, Human/immunology , Pregnancy Complications/blood , Pregnancy Complications/physiopathology , Single Person , Age Factors , Cross-Sectional Studies , Female , Herpes Genitalis/blood , Humans , Immunoglobulin G/blood , Pregnancy , Pregnancy Complications, Infectious/bloodABSTRACT
BACKGROUND: In addition to HPV, high parity and hormonal contraceptives have been associated with cervical cancer (CC). However, most of the evidence comes from retrospective case-control studies. The aim of this study is to prospectively evaluate associations between hormonal factors and risk of developing cervical intraepithelial neoplasia grade 3 (CIN3)/carcinoma in situ (CIS) and invasive cervical cancer (ICC). METHODS AND FINDINGS: We followed a cohort of 308,036 women recruited in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. At enrollment, participants completed a questionnaire and provided serum. After a 9-year median follow-up, 261 ICC and 804 CIN3/CIS cases were reported. In a nested case-control study, the sera from 609 cases and 1,218 matched controls were tested for L1 antibodies against HPV types 11,16,18,31,33,35,45,52,58, and antibodies against Chlamydia trachomatis and Human herpesvirus 2. Multivariate analyses were performed to estimate hazard ratios (HR), odds ratios (OR) and corresponding 95% confidence intervals (CI). The cohort analysis showed that number of full-term pregnancies was positively associated with CIN3/CIS risk (p-trend = 0.03). Duration of oral contraceptives use was associated with a significantly increased risk of both CIN3/CIS and ICC (HR = 1.6 and HR = 1.8 respectively for ≥ 15 years versus never use). Ever use of menopausal hormone therapy was associated with a reduced risk of ICC (HR = 0.5, 95%CI: 0.4-0.8). A non-significant reduced risk of ICC with ever use of intrauterine devices (IUD) was found in the nested case-control analysis (OR = 0.6). Analyses restricted to all cases and HPV seropositive controls yielded similar results, revealing a significant inverse association with IUD for combined CIN3/CIS and ICC (OR = 0.7). CONCLUSIONS: Even though HPV is the necessary cause of CC, our results suggest that several hormonal factors are risk factors for cervical carcinogenesis. Adherence to current cervical cancer screening guidelines should minimize the increased risk of CC associated with these hormonal risk factors.
Subject(s)
Carcinoma, Squamous Cell/epidemiology , Gonadal Steroid Hormones/physiology , Uterine Cervical Dysplasia/epidemiology , Uterine Cervical Neoplasms/epidemiology , Adult , Aged , Antibodies, Viral/blood , Carcinoma, Squamous Cell/physiopathology , Case-Control Studies , Chlamydia Infections/blood , Chlamydia Infections/epidemiology , Chlamydia trachomatis/immunology , Contraceptives, Oral, Hormonal/adverse effects , Female , Follow-Up Studies , Gonadal Steroid Hormones/adverse effects , Herpes Genitalis/blood , Herpes Genitalis/epidemiology , Herpesvirus 2, Human/immunology , Hormone Replacement Therapy/adverse effects , Humans , Intrauterine Devices , Middle Aged , Papillomaviridae/immunology , Papillomavirus Infections/blood , Papillomavirus Infections/epidemiology , Pregnancy , Prospective Studies , Reproductive History , Risk , Uterine Cervical Neoplasms/physiopathology , Young Adult , Uterine Cervical Dysplasia/physiopathologyABSTRACT
Diphenyl diselenide, (PhSe)2 , is an organoselenium compound with pharmacological actions mostly related to antioxidant and anti-inflammatory properties. The study investigated its antiviral and virucidal actions against herpes simplex virus 2 (HSV-2) infection in vitro and in a vaginal infection model in mice. The plaque reduction assay indicated that (PhSe)2 showed virucidal and antiviral actions reducing infectivity in 70.8% and 47%, respectively. The antiviral action of (PhSe)2 against HSV-2 vaginal infection was performed by infecting mice (10(5) PFU/ml(-1) ) at day 6. The treatment with (PhSe)2 (5 mg/kg/day, intragastric [i.g.]) followed 5 days before and for more 5 days after infection. The extravaginal lesion score was evaluated from days 6 to 10. At day 11, animals were killed, and histological evaluation, determination of viral load, and TNF-α and IFN-γ levels were performed in supernatants of homogenized vaginal tissue. The levels of reactive species (RS), protein carbonyl, non-protein thiols (NPSH), nitrate/nitrite (NOx), and malondialdehyde (MDA), and the activities of myeloperoxidase (MPO), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase (GR) were determined. (PhSe)2 reduced the histological damage, extravaginal lesion scores, the viral load of vaginal tissue, and the activity of MPO, but increased the levels of TNF-α, IFN-γ. (PhSe)2 attenuated the increase of RS, MDA, NOx levels and the activity of GR caused by infection. (PhSe)2 also attenuated the reduction of NPSH content and the inhibition of CAT, SOD, and GPx activities. The antiviral action of (PhSe)2 against HSV-2 infection was related to its immunomodulatory, antioxidant, and anti-inflammatory properties. J. Cell. Biochem. 117: 1638-1648, 2016. © 2015 Wiley Periodicals, Inc.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antioxidants/pharmacology , Antiviral Agents/pharmacology , Benzene Derivatives/pharmacology , Herpes Genitalis/drug therapy , Herpesvirus 2, Human , Immunologic Factors/pharmacology , Organoselenium Compounds/pharmacology , Animals , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Female , Herpes Genitalis/blood , MiceABSTRACT
Standard microplate based enzyme-linked immunosorbent assays (ELISA) are widely utilized for various nanomedicine, molecular sensing, and disease screening applications, and this multiwell plate batched analysis dramatically reduces diagnosis costs per patient compared to nonbatched or nonstandard tests. However, their use in resource-limited and field-settings is inhibited by the necessity for relatively large and expensive readout instruments. To mitigate this problem, we created a hand-held and cost-effective cellphone-based colorimetric microplate reader, which uses a 3D-printed opto-mechanical attachment to hold and illuminate a 96-well plate using a light-emitting-diode (LED) array. This LED light is transmitted through each well, and is then collected via 96 individual optical fibers. Captured images of this fiber-bundle are transmitted to our servers through a custom-designed app for processing using a machine learning algorithm, yielding diagnostic results, which are delivered to the user within â¼1 min per 96-well plate, and are visualized using the same app. We successfully tested this mobile platform in a clinical microbiology laboratory using FDA-approved mumps IgG, measles IgG, and herpes simplex virus IgG (HSV-1 and HSV-2) ELISA tests using a total of 567 and 571 patient samples for training and blind testing, respectively, and achieved an accuracy of 99.6%, 98.6%, 99.4%, and 99.4% for mumps, measles, HSV-1, and HSV-2 tests, respectively. This cost-effective and hand-held platform could assist health-care professionals to perform high-throughput disease screening or tracking of vaccination campaigns at the point-of-care, even in resource-poor and field-settings. Also, its intrinsic wireless connectivity can serve epidemiological studies, generating spatiotemporal maps of disease prevalence and immunity.
Subject(s)
Antibodies, Viral/blood , Computers, Handheld/economics , Enzyme-Linked Immunosorbent Assay/methods , Immunoglobulin G/blood , Point-of-Care Systems/economics , Cell Phone/instrumentation , Colorimetry/economics , Colorimetry/instrumentation , Colorimetry/methods , Enzyme-Linked Immunosorbent Assay/economics , Enzyme-Linked Immunosorbent Assay/instrumentation , Herpes Genitalis/blood , Herpes Genitalis/diagnosis , Herpes Genitalis/immunology , Herpes Simplex/blood , Herpes Simplex/diagnosis , Herpes Simplex/immunology , Humans , Machine Learning , Measles/blood , Measles/diagnosis , Measles/immunology , Mobile Applications , Mumps/blood , Mumps/diagnosis , Mumps/immunology , Optical Fibers , Point-of-Care Testing , Sensitivity and SpecificityABSTRACT
BACKGROUND: In a randomized controlled trial (RCT) in a blood bank in São Paulo, we tested the hypotheses that offering client-centered human immunodeficiency virus (HIV) counseling and testing to blood donors would: 1) reduce the risk of HIV contamination in the blood supply by diverting higher-risk, test-seeking donors away from donation and 2) increase return for results and referrals to care. STUDY DESIGN AND METHODS: We randomly selected weeks between August 2012 and May 2013 when donors were offered HIV counseling and testing (n = 6298), leaving usual procedure weeks as control (n = 5569). RESULTS: Few candidate donors chose HIV testing (n = 81, 1.3%). There was no significant difference in herpes simplex virus Type 2 (HSV-2) prevalence (a marker of sexual risk) among donors during intervention weeks compared to control (10.4% vs. 11.1%, p = 0.245). No donor choosing testing was HIV infected, and there was no difference in HSV-2 prevalence between testers and donors (9.9% vs. 10.4%, p = 0.887). Returning for positive results did not differ between testers and donors (three of three vs. 58 of 80, p = 0.386). A higher proportion of donors acknowledged that HIV testing was a strong motivation to donate during intervention weeks compared to control (2.6% vs. 2.0%, p = 0.032). CONCLUSION: The evidence of our RCT is that offering HIV counseling and testing at the time of donation would not change the risk of contamination in the blood supply, nor improve results disclosure and referral to care.
Subject(s)
AIDS Serodiagnosis , Blood Donors/psychology , Blood Safety , Counseling , HIV Infections/prevention & control , Herpes Genitalis/epidemiology , Herpesvirus 2, Human/isolation & purification , Truth Disclosure , Adult , Biomarkers , Blood Donors/statistics & numerical data , Brazil/epidemiology , Female , HIV Infections/blood , HIV Infections/epidemiology , HIV Infections/transmission , HIV Seroprevalence , Health Knowledge, Attitudes, Practice , Herpes Genitalis/blood , Herpes Genitalis/transmission , Humans , Male , Patient Acceptance of Health Care , Referral and Consultation , Risk-Taking , Seroepidemiologic Studies , Sexual Behavior , Surveys and QuestionnairesABSTRACT
OBJECTIVES: Herpes simplex virus-2 (HSV-2) and syphilis are associated with increased risk of HIV, highlighting the importance of understanding their transmission dynamics. In India, most studies of HSV-2 and syphilis incidence are in high-risk populations and may not accurately reflect infectious activity. In this study, we aim to define HSV-2/syphilis incidence and risk factors in a population sample. METHODS: We conducted a longitudinal population-based survey in Andhra Pradesh, India, in two rounds: 2004-2005 and 2010-2011. Sociodemographic and behavioural data were collected, and dried blood spots tested for HSV-2 and Treponema pallidum IgG. After calculating sexually transmitted infection (STI) incidence, associated factors were assessed using modified Poisson regression and within-couple transmission rates modelled using seroconcordance/discordance data. RESULTS: 12,617 adults participated at baseline with 8494 at follow-up. Incidence of HSV-2 and syphilis per 1000 person-years was 25.6 (95% CI 24.1 to 27.2) and 3.00 (95% CI 2.52 to 3.54). Incidence of HSV-2 was higher in women vs. men (31.1 vs. 20.2) and in rural vs urban residents (31.1 vs 19.0) (p<0.05 for both). STI seroincidence increased in a step-wise fashion with age and was associated with spousal seropositivity for both sexes (incidence rate ratio (IRR) 2.59 to 6.78). Within couples the rate of transmission per 1000 couple-years from men to women vs. women to men was higher for HSV-2 (193.3 vs. 119.0) compared with syphilis (27.6 vs. 198.8), p<0.05 for both. CONCLUSIONS: HSV-2 has higher incidence among subpopulations such as women, rural residents and older-aged individuals, suggesting a need for more generalised STI prevention approaches among populations traditionally considered low risk.
Subject(s)
HIV Infections/epidemiology , Herpes Genitalis/epidemiology , Herpesvirus 2, Human/isolation & purification , Syphilis/epidemiology , Treponema pallidum/isolation & purification , Adult , Female , Follow-Up Studies , HIV Infections/blood , HIV Infections/prevention & control , Herpes Genitalis/blood , Humans , Incidence , India/epidemiology , Longitudinal Studies , Male , Risk Factors , Seroepidemiologic Studies , Sexual Behavior , Syphilis/bloodABSTRACT
BACKGROUND: This study is the first documented prevalence of IgG antibody against HSV-1&-2 in Port Harcourt, Nigeria and thus provides baseline data for future in-depth studies on HSV infection in South-South, Nigeria. OBJECTIVE: This study determined the seropositivity and determinants of serum IgG antibody against HSV-1 & HIV-2 among pregnant women attending BMSH, Port Harcourt, Rivers State, Nigeria. METHODS: Serum samples from 180 pregnant women attending antenatal clinic at Braithwaite Memorial Specialist Hospital (BMSH) in Port Harcourt, Nigeria. Serum samples were analysed with commercial HSV type-1&-2 specific IgG Enzyme Linked Immunosorbent Assay (ELISA) kits. Chi-square analysis was used to determine the association of infection with socio-demographic variables. RESULTS: Of the 180 pregnant women, 179 (99.4%) were seropositive and 1(0.6%) was seronegative for HSV 1&2 IgG antibody. No statistical association existed between the prevalence of HSV-1&-2 IgG antibodies and the socio-demographic variables studied (p>0.05) except for marital status which was significantly associated (p<0.05). CONCLUSION: Our data shows that HSV-1 & 2 seropositivity among pregnant women in Port Harcourt is high; thus serological screening for HSV-1&-2 might be advisable for antenatal attendees.
Subject(s)
Antibodies, Viral/blood , Herpes Genitalis/blood , Herpes Simplex/blood , Herpesvirus 1, Human/immunology , Herpesvirus 2, Human/immunology , Adult , Enzyme-Linked Immunosorbent Assay , Female , Herpes Genitalis/epidemiology , Herpes Genitalis/immunology , Herpes Simplex/epidemiology , Herpes Simplex/immunology , Humans , Immunoglobulin G/blood , Marital Status , Nigeria/epidemiology , Pregnancy/blood , Pregnancy/immunology , Prevalence , Seroepidemiologic Studies , Young AdultABSTRACT
The positive clinical, serolgical and immunological effects of Glutamyl-Triptophan in patients on persistent herpes virus infections are shown. Treatment resulted in the increase of avidity on HSV 1, HSV 2, CMV, EBV antibody, the levels of CD3+-, ICD8+-, CD16+-, CD3+HLA-DR+- (%, abs) and.CD3+CD25t-cells (%), that indicates the optimization of the immune systemdata. The data received allow to recommend Bestim for patients with persistent herpes virus infections.
Subject(s)
Antibodies, Viral/blood , Antiviral Agents/therapeutic use , Cytomegalovirus Infections/drug therapy , Dipeptides/therapeutic use , Epstein-Barr Virus Infections/drug therapy , Herpes Genitalis/drug therapy , Herpes Simplex/drug therapy , Immunologic Factors/therapeutic use , Acyclovir/analogs & derivatives , Acyclovir/therapeutic use , Adult , Antibodies, Viral/biosynthesis , Antigens, CD/genetics , Antigens, CD/immunology , Case-Control Studies , Chronic Disease , Cytomegalovirus/immunology , Cytomegalovirus Infections/blood , Cytomegalovirus Infections/immunology , Cytomegalovirus Infections/virology , Epstein-Barr Virus Infections/blood , Epstein-Barr Virus Infections/immunology , Epstein-Barr Virus Infections/virology , Female , Gene Expression , Herpes Genitalis/blood , Herpes Genitalis/immunology , Herpes Genitalis/virology , Herpes Simplex/blood , Herpes Simplex/immunology , Herpes Simplex/virology , Herpesvirus 1, Human/immunology , Herpesvirus 2, Human/immunology , Herpesvirus 4, Human/immunology , Humans , Immunity, Cellular/drug effects , Immunity, Humoral/drug effects , Male , Middle Aged , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , T-Lymphocytes/virology , Valacyclovir , Valine/analogs & derivatives , Valine/therapeutic useABSTRACT
The present study was undertaken for the purpose of finding IgM antibodies against HSV-1 and 2 infections among pregnant women and also to evaluate correlation of Serum HSV-1 and 2 IgM in these pregnant women. A total of 180 pregnant women attending antenatal clinic at Braithwaite Memorial Specialist Hospital (BMSH) in Port Harcourt, Nigeria were consecutively recruited, after they had given consents to participate in the study. Serum of each sample was assayed for HSV-1&2 IgM antibody using a commercial ELISA. Five (2.8%) of the pregnant women were positive for IgM antibody against HSV-1&2. Marital status mainly correlated (χ(2) = 221.5, P < 0.05) with HSV-2 infection and HSV-1/HSV-2 co-infection. Age, educational level, occupation, and gestation were not consistently associated (P>0.05) with HSV-1/HSV-2 infection and co-infection. We also observed a high overall anti-HSV-1&2 IgM seronegativity of 97.2% among these pregnant women. Group-specific seronegativity was also high ranging from 93.3-100%. Although the age-groups significantly differed, none of their variables showed statistical association with the seronegativity. This represents the first analysis of HSV IgM antibody reported in Port Harcourt, Nigeria and has important public health implications, particularly for pregnant women. Consideration of this information would benefit physicians providing primary gynecological and obstetric care to this population of women.
Subject(s)
Antibodies, Viral/blood , Herpes Genitalis/blood , Herpes Simplex/blood , Herpesvirus 1, Human/immunology , Herpesvirus 2, Human/immunology , Immunoglobulin M/blood , Adult , Educational Status , Employment , Female , Herpes Genitalis/epidemiology , Herpes Genitalis/immunology , Herpes Simplex/epidemiology , Herpes Simplex/immunology , Humans , Marital Status , Nigeria/epidemiology , Pregnancy/blood , Pregnancy/immunology , Seroepidemiologic StudiesABSTRACT
BACKGROUND: A rapid point-of-care test with high sensitivity and specificity is required in order to fulfill the need for early detection and screening of Herpes simplex virus type 2 (HSV-2) infection among patients with genital ulcer disease (GUD), for better management and control of virus transmission. METHODS: The goal of this study is to evaluate the performance of the commercially available HerpeSelect Express rapid test in comparison with three ELISA assays: HerpeSelect ELISA, Kalon HSV-2 glycoprotein G2 assay, and monoclonal antibody blocking enzyme immunoassay, which was used as the gold standard for the detection of HSV-2 antibodies. RESULTS: This study showed high sensitivity (ranging from 82.6 to 100%) and specificity (100%) of the HerpeSelect Express rapid test when compared to the three ELISA assays. The agreement between the HerpeSelect Express rapid test with the three ELISAs ranged from 93.3 to 100%. CONCLUSION: The HerpeSelect Express rapid test has adequate sensitivity and specificity for confirming HSV-2 infection in patients with GUD, indicating its suitability for epidemiological studies.
Subject(s)
Antibodies, Viral/blood , Glycoproteins/immunology , Herpes Genitalis , Herpesvirus 2, Human/metabolism , Ulcer , Viral Proteins/immunology , Adult , Enzyme-Linked Immunosorbent Assay , Female , Herpes Genitalis/blood , Herpes Genitalis/complications , Herpes Genitalis/virology , Herpesvirus 2, Human/immunology , Humans , Male , Middle Aged , Predictive Value of Tests , Sensitivity and Specificity , Statistics, Nonparametric , Ulcer/blood , Ulcer/complications , Ulcer/virologyABSTRACT
HSV-2 infection is common and generally asymptomatic, but it is associated with increased HIV susceptibility and disease progression. This may relate to herpes-mediated changes in genital and systemic immunology. Cervical cytobrushes and blood were collected from HIV-uninfected African/Caribbean women in Toronto, and immune cell subsets were enumerated blindly by flow cytometry. Immune differences between groups were assessed by univariate analysis and confirmed using a multivariate model. Study participants consisted of 46 women, of whom 54% were infected with HSV-2. T cell activation and expression of the mucosal homing integrin α4ß7 (19.60 versus 8.76%; p < 0.001) were increased in the blood of HSV-2-infected women. Furthermore, expression of α4ß7 on blood T cells correlated with increased numbers of activated (coexpressing CD38/HLA-DR; p = 0.004) and CCR5(+) (p = 0.005) cervical CD4(+) T cells. HSV-2-infected women exhibited an increase in the number of cervical CD4(+) T cells (715 versus 262 cells/cytobrush; p = 0.016), as well as an increase in the number and proportion of cervical CD4(+) T cells that expressed CCR5(+) (406 versus 131 cells, p = 0.001; and 50.70 versus 34.90%, p = 0.004) and were activated (112 versus 13 cells, p < 0.001; and 9.84 versus 4.86%, p = 0.009). Mannose receptor expression also was increased on cervical dendritic cell subsets. In conclusion, asymptomatic HSV-2 infection was associated with significant systemic and genital immune changes, including increased immune activation and systemic α4ß7 expression; correlation of the latter with highly HIV-susceptible CD4(+) T cell subsets in the cervix may provide a mechanism for the increased HIV susceptibility observed in asymptomatic HSV-2-infected women.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , Cervix Uteri/immunology , Herpes Genitalis/immunology , Herpesvirus 2, Human/immunology , Integrins/immunology , T-Lymphocyte Subsets/immunology , Adult , CD4-Positive T-Lymphocytes/metabolism , CD4-Positive T-Lymphocytes/pathology , Cervix Uteri/metabolism , Cervix Uteri/pathology , Cervix Uteri/virology , Dendritic Cells/immunology , Dendritic Cells/metabolism , Dendritic Cells/pathology , Female , Gene Expression Regulation/immunology , Herpes Genitalis/blood , Herpes Genitalis/genetics , Herpes Genitalis/pathology , Herpesvirus 2, Human/genetics , Herpesvirus 2, Human/metabolism , Humans , Integrins/blood , Male , Middle Aged , T-Lymphocyte Subsets/metabolism , T-Lymphocyte Subsets/pathologyABSTRACT
BACKGROUND: Previously we conducted a double-blind controlled, randomized efficacy field trial of gD-2 HSV vaccine adjuvanted with ASO4 in 8323 women. Subjects had been previously selected to be seronegative for HSV-1 and HSV-2. We found that vaccine was 82% protective against HSV-1 genital disease, but offered no significant protection against HSV-2 genital disease. METHODS: To better understand the results of the efficacy study, post-vaccination anti-gD-2 antibody concentrations from all HSV infected subjects and matched uninfected controls were measured. Three models were used to determine whether thes responses correlated with protection against HSV infection or disease. Similarly, cellular immune responses from a subset of subjects and matched controls were evaluated for a correlation with HSV protection. RESULTS: Antibodies to gD-2 correlated with protection against HSV-1 infection with higher antibody concentration associated with higher efficacy. Cellular immune responses to gD-2 did not correlate with protection. CONCLUSIONS: The protection against HSV-1 infection observed in the Herpevac Trial for Women was associated with antibodies directed against the vaccine. Clinical Trials Registration NCT00057330.
Subject(s)
Herpes Genitalis/immunology , Herpes Genitalis/prevention & control , Herpes Simplex Virus Vaccines/administration & dosage , Herpes Simplex Virus Vaccines/immunology , Herpesvirus 1, Human/immunology , Antibodies, Viral/biosynthesis , Antibodies, Viral/blood , Antibodies, Viral/immunology , Case-Control Studies , Cytokines/blood , Double-Blind Method , Enzyme-Linked Immunosorbent Assay , Female , Herpes Genitalis/blood , Humans , Prospective StudiesABSTRACT
To evaluate prospectively the association between serological markers of selected infections, including HPV, and risk of developing cervical cancer (CC) and precancer, we performed a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) study that included 184 cases of invasive CC (ICC), 425 cases of cervical intraepithelial neoplasia (CIN) grade 3 or carcinoma in situ (CIS), and 1,218 matched control women. At enrollment participants completed lifestyle questionnaires and provided sera. Subjects were followed-up for a median of 9 years. Immunoassays were used to detect serum antibodies to Human Herpes Virus 2 (HHV-2), Chlamydia trachomatis (CT), Chlamydia pneumoniae, L1 proteins of mucosal and cutaneous HPV types, E6/E7 proteins of HPV16/18, as well as to four polyomaviruses. Adjusted odds ratios (OR) [and 95% confidence intervals (CI)] for CIN3/CIS and ICC risk were respectively: 1.6 (1.2-2.0) and 1.8 (1.1-2.7) for L1 seropositivity to any mucosal HPV type, 1.0 (0.4-2.4) and 7.4 (2.8-19.7) for E6 seropositivity to HPV16/18, 1.3 (0.9-1.9) and 2.3 (1.3-4.1) for CT seropositivity, and 1.4 (1.0-2.0) and 1.5 (0.9-2.6) for HHV-2 seropositivity. The highest OR for ICC was observed for HPV16 E6 seropositivity [OR = 10.2 (3.3-31.1)]. Increasing number of sexually transmitted infections (STIs) was associated with increasing risk. Non-STIs were not associated with CC risk. In conclusion, this large prospective study confirms the important role of HPV and a possible contribution of CT and HHV-2 in cervical carcinogenesis. It further identifies HPV16 E6 seropositivity as the strongest marker to predict ICC well before disease development.
Subject(s)
Sexually Transmitted Diseases/complications , Uterine Cervical Neoplasms/microbiology , Adult , Aged , Biomarkers, Tumor/blood , Case-Control Studies , Chlamydia Infections/blood , Chlamydia Infections/complications , Chlamydia Infections/epidemiology , Cohort Studies , Female , Herpes Genitalis/blood , Herpes Genitalis/complications , Herpes Genitalis/epidemiology , Humans , Middle Aged , Papillomavirus Infections/blood , Papillomavirus Infections/complications , Papillomavirus Infections/epidemiology , Seroepidemiologic Studies , Sexually Transmitted Diseases/blood , Sexually Transmitted Diseases/epidemiology , Uterine Cervical Neoplasms/blood , Young Adult , Uterine Cervical Dysplasia/blood , Uterine Cervical Dysplasia/microbiologyABSTRACT
Amenamevir is the international non-proprietary name for ASP2151 synthesized by Astellas Pharma, Inc. It is a structurally novel class of helicase-primase inhibitor and demonstrated more potency in vitro anti-viral activity with low cytotoxicity against varicella-zoster virus (VZV), herpes simplex virus type 1 (HSV-1), and herpes simplex virus type 2 (HSV-2) than acyclovir (ACV). Phase II randomized trial assessed the safety and efficacy of ASP2151 for episodic therapy of recurrent genital herpes was conducted. Participants self-initiated with ASP2151 (100, 200, or 400 mg daily for 3 days), ASP2151 (1,200 mg as a single dose), placebo for 3 days, or Valacyclovir (500 mg twice daily for 3 days). We present a first population pharmacokinetic (PPK) modeling analysis of Amenamevir for genital herpes patients. The final model retained the effect of Weight and Albumin on CL. Statistical analysis between pharmacokinetics and clinical efficacies was done by using the time above 200 ng/mL (T200 ). T200 derived from the final PPK model to consider the correlation with Time to lesion healing and viral shedding. This finding suggested that it could be necessary to maintain the Amenamevir concentration above the threshold level to prevent the virus replication.
Subject(s)
Antiviral Agents/pharmacokinetics , Herpes Genitalis/drug therapy , Herpesvirus 2, Human/drug effects , Models, Biological , Nonlinear Dynamics , Oxadiazoles/pharmacokinetics , Antiviral Agents/administration & dosage , Antiviral Agents/adverse effects , Antiviral Agents/blood , Drug Administration Schedule , Drug Monitoring/methods , Female , Herpes Genitalis/blood , Herpes Genitalis/diagnosis , Herpes Genitalis/virology , Herpesvirus 2, Human/growth & development , Humans , Male , Oxadiazoles/administration & dosage , Oxadiazoles/adverse effects , Oxadiazoles/blood , Recurrence , Treatment Outcome , Viral LoadABSTRACT
BACKGROUND: Herpes simplex virus type 2 (HSV-2) is a common co-infection among HIV-infected adults that is hypothesized to accelerate HIV disease progression. METHODS: We searched Medline, EMBASE, relevant conference proceedings (2006-12) and bibliographies of identified studies without language restriction for cohort studies examining the impact of HSV-2 on highly active antiretroviral therapy-untreated HIV disease in adults. The exposure of interest was HSV-2 seropositivity or clinical/laboratory markers of HSV-2 activity. The primary outcome was HIV disease progression, defined as antiretroviral initiation, development of AIDS/opportunistic infection, or progression to CD4 count thresholds (≤ 200 or ≤ 350 cells/mm(3)). Secondary outcomes included HIV plasma viral load and CD4 count. RESULTS: Seven studies were included. No definitive relationship was observed between HSV-2 seropositivity and time to antiretroviral initiation (n=2 studies), CD4 ≤ 350 (n=1), CD4 ≤ 200 (n=1), death (n=1), viral load (n=6) or CD4 count (n=3). Although two studies each observed trends towards accelerated progression to clinical AIDS/opportunistic infection in HSV-2 seropositives, with pooled unadjusted hazard ratio=1.85 (95% CI=1.12,3.06; I2=2%), most OIs observed in the study for which data were available can occur at high CD4 counts and may not represent HIV progression. In contrast, a single study HSV-2 disease activity found that the presence of genital HSV-2 DNA was associated with a 0.4 log copies/mL increase in HIV viral load. CONCLUSIONS: Despite an observation that HSV-2 activity is associated with increased HIV viral load, definitive evidence linking HSV-2 seropositivity to accelerated HIV disease progression is lacking. The attenuating effects of acyclovir on HIV disease progression observed in recent trials may result both from direct anti-HIV activity as well as from indirect benefits of HSV-2 suppression.
Subject(s)
HIV Infections/virology , Herpes Genitalis/virology , Herpesvirus 2, Human/isolation & purification , CD4 Lymphocyte Count , Coinfection/blood , Coinfection/pathology , Coinfection/virology , Disease Progression , HIV Infections/blood , HIV Infections/pathology , Herpes Genitalis/blood , Herpes Genitalis/pathology , Humans , Viral LoadABSTRACT
Protein microarrays have been developed to study antibody reactivity against a large number of antigens, demonstrating extensive perspective for clinical application. We developed a viral antigen array by spotting four recombinant antigens and synthetic peptide, including glycoprotein G of herpes simplex virus (HSV) type 1 and 2, phosphoprotein 150 of cytomegalovirus (CMV), Rubella virus (RV) core plus glycoprotein E1 and E2 as well as a E1 peptide with the optimal concentrations on activated glass slides to simultaneously detect IgG and IgM against HSV1, HSV2, CMV and RV in clinical specimens of sera and cerebrospinal fluids (CSFs). The positive reference sera were initially used to measure the sensitivity and specificity of the array with the optimal conditions. Then clinical specimens of 144 sera and 93 CSFs were tested for IgG and IgM antibodies directed against HSV1, HSV2, CMV and RV by the antigen array. Specificity of the antigen array for viral antibodies detection was satisfying compared to commercial ELISA kits but sensitivity of the array varied relying on quality and antigenic epitopes of the spotting antigens. In short, the recombinant antigen array has potential to simultaneous detect multiple viral antibodies using minute amount (3 µl) of samples, which holds the particularly advantage to detect viral antibodies in clinical CSFs being suspicious of neonatal meningitis and encephalitis.